The human immune system tolerates infused horse antibodies without adverse reaction
the verdict
REFUTED
the evidence says no
confidence 12/100
The claim that the human immune system tolerates infused horse antibodies without adverse reaction is refuted by clinical evidence showing that heterologous proteins frequently trigger immune responses, hypersensitivity, and adverse events.
Evidence against · 3
History of Envenoming Therapy and Current Perspectives.
2019 · cited by 91
Paper 0 discusses the historical reliance on animal-derived antibodies and the persistent challenges of immunogenicity associated with heterologous serum therapy.
See more details
More against · 2
Anti-SARS-CoV-2 equine F (Ab')<sub>2</sub> immunoglobulin as a possible therapy for COVID-19.
2022 · cited by 13
Paper 7 describes the development of equine F(ab')2 fragments for COVID-19 and highlights the necessity of processing/purification to mitigate adverse immunological reactions compared to whole immunoglobulins.
Hyperimmune immunoglobulin for people with COVID-19.
2023 · cited by 11
Paper 8 reviews clinical trials of animal-derived polyclonal antibodies and notes that while they are used therapeutically, patients receiving heterologous preparations can experience adverse immune-related events and hypersensitivity risks.